Bupivacaine

證據等級: L5

預測適應症: 4 個

Bupivacaine: From Local Anesthesia to Acrodermatitis Chronica Atrophicans

One-Sentence Summary

Bupivacaine is a long-acting local anesthetic widely used for regional anesthesia, nerve blocks, and perioperative pain management. The TxGNN model predicts it may be effective for Acrodermatitis Chronica Atrophicans (ACA), a late-stage cutaneous manifestation of Lyme borreliosis. However, there are currently 0 clinical trials and 0 publications supporting this direction, making the evidence base extremely limited.

Quick Overview

Item	Content
Original Indication	Local anesthesia / regional anesthesia (not registered in India; based on established pharmacological use)
Predicted New Indication	Acrodermatitis Chronica Atrophicans
TxGNN Prediction Score	99.23%
Evidence Level	L5
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this analysis. Based on known pharmacological information, Bupivacaine is a long-acting amide-type local anesthetic that blocks voltage-gated sodium channels (Nav), thereby inhibiting the propagation of action potentials in sensory and motor neurons. Beyond its anesthetic effect, local anesthetics as a class are known to exert secondary anti-inflammatory properties — including inhibition of NF-κB signalling and downregulation of pro-inflammatory cytokines such as IL-6 and TNF-α.

Acrodermatitis chronica atrophicans (ACA) is a chronic skin condition caused by persistent Borrelia burgdorferi infection and is characterised by progressive dermal atrophy, fibrosis, and ongoing local inflammation. In theory, the anti-inflammatory side effects of local anesthetics could provide some symptomatic relief of the inflammatory component of ACA. However, the core pathology — spirochaetal persistence and connective tissue degradation — has no known intersection with sodium channel blockade.

The high TxGNN score most likely reflects shared topological features between skin inflammation nodes in the knowledge graph, rather than a genuine pharmacological link. This is a case where graph-based prediction may be capturing indirect structural associations rather than mechanistically actionable biology, and the prediction should be interpreted with significant caution.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Bupivacaine currently has no registered products in India. No authorization records are available.

Safety Considerations

Drug Interactions: A total of 56 drug interactions have been identified for Bupivacaine. Key interactions include:

Interacting Drug	Interaction Level	Clinical Note
Aprepitant	Moderate	CYP3A4 inhibition may increase bupivacaine plasma levels
Morphine (liposomal)	Moderate	Combined CNS/respiratory depression risk with concurrent opioid use
Dexamethasone	Unknown	Often co-administered for nerve blocks; interaction profile requires monitoring
Ondansetron	Unknown	QT-interval prolongation risk may be additive
Metronidazole	Unknown	Potential CNS toxicity interaction; use with caution
Atropine	Unknown	Anticholinergic effects may mask signs of local anesthetic toxicity
Naloxone	Unknown	Used in overdose management; interaction monitoring advised
Metoclopramide	Unknown	Potential for additive neurotoxicity
Triamcinolone	Unknown	Commonly co-administered in joint/epidural blocks; systemic interaction unclear
Vancomycin	Unknown	No established interaction, but concurrent use in surgical settings warrants monitoring

For complete warnings and contraindications, please refer to the approved package insert, as formal label data was not available in this Evidence Pack.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical trial, observational, or published literature evidence supporting the use of Bupivacaine in acrodermatitis chronica atrophicans. The mechanistic link is extremely weak — the TxGNN prediction appears to be driven by shared graph topology in the skin inflammation domain rather than a real pharmacological rationale. The safety profile of systemic Bupivacaine administration also introduces meaningful risk without any evidence-based benefit to justify progression.

To proceed, the following is needed:

Formal MOA documentation from DrugBank (DG002) to enable mechanistic plausibility assessment
Retrieval and parsing of the approved package insert to populate key warnings and contraindications (DG001)
A hypothesis-generating preclinical study (in vitro or animal model) demonstrating any bupivacaine effect on Borrelia-induced skin inflammation or fibrosis
Exploration of whether IV lidocaine (same class, more systemic safety data) has any published evidence in ACA or related spirochaetal skin conditions — which would strengthen or weaken the class-level rationale
If proceeding to exploratory investigation, a risk assessment for systemic administration routes should be conducted, given bupivacaine’s known cardiotoxicity at supratherapeutic levels
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.